Recombinant interferon ?-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients

1993 ◽  
Vol 37 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Ilan G. Ron ◽  
Moshe J. Inbar ◽  
Mordechai Gutman ◽  
Ofer Merimsky ◽  
Samario Chaitchik
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Recombinant Interferon

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 ◽  
Vol 9 (8) ◽  
pp. 1403-1408 ◽  
Author(s):  
C I Falkson ◽  
G Falkson ◽  
H C Falkson
Keyword(s):  
Malignant Melanoma ◽  
Treatment Failure ◽  
Partial Remission ◽  
Performance Status ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Time To Treatment Failure ◽  
Metastatic Sites

Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.

Treatment of Metastatic Malignant Melanoma with Recombinant Interferon Alpha 2

Immunobiology ◽  
1986 ◽  
Vol 172 (3-5) ◽  
pp. 275-282 ◽  
Author(s):  
W.A. Robinson ◽  
T.I. Mughal ◽  
M.R. Thomas ◽  
Melinda Johnson ◽  
R.J. Spiegel
Keyword(s):  
Malignant Melanoma ◽  
Interferon Alpha ◽  
Metastatic Malignant Melanoma ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070)

2007 ◽  
Vol 17 (5) ◽  
pp. 329-331 ◽  
Author(s):  
Martina Baur ◽  
Margit Gneist ◽  
Takashi Owa ◽  
Christian Dittrich
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma

scholarly journals A 60-Year-Old Female With Metastatic Malignant Melanoma of the Scalp Responding to Ipilimumab

2018 ◽  
Vol 4 ◽  
pp. 2513826X1775111
Author(s):  
Sarah Lohrenz ◽  
Jennifer Crawford ◽  
Shawki Souf
Keyword(s):  
Malignant Melanoma ◽  
Treatment Options ◽  
Poor Response ◽  
Metastatic Malignant Melanoma ◽  
Advanced Stage ◽  
Free Response ◽  
First Case ◽  
Promising Treatment ◽  
Novel Concept

Melanoma is an aggressive disease that accounts for approximately 75% of skin cancer-related deaths. In the past, treatment options for patients with advanced stage melanoma have been limited with poor response rate and failure to improve overall survival (OS). Immunotherapy is a promising treatment that has been shown to improve OS and in cases produce durable remissions—a novel concept in the treatment of advanced melanoma. We report a case of advanced stage metastatic malignant melanoma of the scalp with a durable (31 months) response to ipilimumab immunotherapy. This is the first case study reporting long-term, progression-free response to ipilimumab in metastatic melanoma without side effects of therapy. This case adds to the evidence supporting early referral and initiation of ipilimumab in patients who can tolerate it, with the goal of producing a sustained treatment-free response and preserved quality of life.

Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b

1987 ◽  
Vol 5 (S4) ◽  
Author(s):  
T. Dorval ◽  
T. Palangie ◽  
M. Jouve ◽  
E. Garcia-Giralt ◽  
E. Falcoff ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Recombinant Interferon

51 20-year long-term results of the use of external beam radiotherapy for primary advanced, recurrent and metastatic malignant melanoma

1997 ◽  
Vol 39 (2) ◽  
pp. 160
Author(s):  
M.Heinrich Seegenschmiedt ◽  
Ludwig Keilholz ◽  
Annelore Altendorf-Hofmann ◽  
Hermann Schell ◽  
Christian Wittekind ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
External Beam Radiotherapy ◽  
Metastatic Malignant Melanoma ◽  
Long Term Results ◽  
External Beam

Metastatic Malignant Melanoma of the Gallbladder Presenting as Biliary Colic: A Case Report and Review of Literature

2007 ◽  
Vol 73 (8) ◽  
pp. 833-835 ◽  
Author(s):  
Justin K. Nelms ◽  
Jitesh A. Patel ◽  
Donald P. Atkinson ◽  
John J. Raves
Keyword(s):  
Malignant Melanoma ◽  
Abdominal Ultrasound ◽  
Metastatic Malignant Melanoma ◽  
Biliary Colic ◽  
Review Of Literature ◽  
Term Survival ◽  
Metastatic Lesions ◽  
Common Cancer ◽  
Melanoma Metastases

Malignant melanoma (MM) is the most common cancer to metastasize to the gastrointestinal tract. Autopsy reports estimate that up to 15 per cent of these patients also have gallbladder metastases, and MM accounts for up to 60 per cent of metastatic lesions to the gallbladder. However, despite its prevalence, MM to the gallbladder is reported only sparingly in the literature. This discordance may be explained by the fact that these lesions are seldom symptomatic. Abdominal ultrasound remains the modality of choice in studying gallbladder pathology and has the ability to define metastatic lesions. The effect of screening for gallbladder metastases on improving survival is not well defined, and thus its role remains controversial. Cholecystectomy for melanoma metastases to the gallbladder seems to be mostly palliative, although there have been isolated reports of excellent long-term survival outcomes. The role for immunotherapy and chemotherapy in this population is not well defined, and overall prognosis is poor. Recent reports have advocated laparoscopic cholecystectomy as the treatment of choice, though there remains a concern for peritoneal port site seeding. We present the case of a 48-year-old man with MM metastatic to the gallbladder and a brief review of the literature.

scholarly journals Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

2018 ◽  
pp. 1-5 ◽  
Author(s):  
Sonia Brugnara ◽  
Mariacristina Sicher ◽  
Elena Maria Bonandini ◽  
Davide Donner ◽  
Franca Chierichetti ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Complete Response ◽  
Metastatic Malignant Melanoma ◽  
Treatment Cessation
Sign in / Sign up

Export Citation Format

Share Document